Sustained Effectiveness of Rotavirus Vaccine Against Very Severe Rotavirus Disease Through the Second Year of Life, Bolivia 2013–2014

Pringle, Kimberly; Patzi, Maritza; Tate, Jacqueline E.; Rojas, Volga Iniguez; Patel, Manish; Jordan, Lucia Inchauste; Montesano, Raul; Zarate, Adolfo; Oliveira, Lúcia de; Parashar, Umesh D.

doi:10.1093/cid/civ1026

Cited by 28 publications

(19 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Latin America, countries including Nicaragua and Bolivia, and in Africa; Malawi, Ghana, Botswana, Rwanda, and Zambia have successfully demonstrated reductions in rotavirus associated hospitalizations (45–75%) (Table 1) [26], [27], [28], [29], [30], [31], [32], [33]. In a number of studies in these countries however, a decline in vaccine effectiveness in the second year of life has been reported.…”

Section: Rotavirus Disease Is a Vaccine Preventable Diseasementioning

confidence: 99%

The rotavirus vaccine development pipeline

Kirkwood

Carey

et al. 2019

Vaccine

108

162

View full text Add to dashboard Cite

Rotavirus disease is a leading global cause of mortality and morbidity in children under 5years of age. The effectiveness of the two globally used oral rotavirus vaccines quickly became apparent when introduced into both developed and developing countries, with significant reductions in rotavirus-associated mortality and hospitalizations. However, the effectiveness and impact of the vaccines is reduced in developing country settings, where the burden and mortality is highest. New rotavirus vaccines, including live oral rotavirus candidates and non-replicating approaches continue to be developed, with the major aim to improve the global supply of rotavirus vaccines and for local implementation, and to improve vaccine effectiveness in developing settings. This review provides an overview of the new rotavirus vaccines in development by developing country manufacturers and provides a rationale why newer candidates continue to be explored. It describes the new live oral rotavirus vaccine candidates as well as the non-replicating rotavirus vaccines that are furthest along in development.

show abstract

Section: Rotavirus Disease Is a Vaccine Preventable Diseasementioning

confidence: 99%

The rotavirus vaccine development pipeline

Kirkwood

Carey

et al. 2019

Vaccine

108

162

View full text Add to dashboard Cite

show abstract

“…Whether the [25][26][27] Although P [4], P [6], and P [8] antigens are extensively immunologically related, vaccination with the current P[8]-based vaccine elicited a strong neutralising antibody response against the two strains expressing the vaccine homologous P [8] type, but only a modest neutralising antibody response to heterologous P [4] strains, and no response to the P [6] strain. Although live oral rotavirus vaccines have been shown to provide protection against rotavirus gastroenteritis caused by rotavirus strains with and without G and P genotypes shared with the vaccine strain, 28,29 this crossprotection might not occur with subunit vaccines, and a multivalent vaccine with P [4], P [6], and P [8] antigens might be required to provide protection against the common circulating rotavirus strains. Therefore, we are undertaking a multicentre study in South Africa to investigate the safety and immunogenicity of a trivalent P2-VP8-P[4/6/8] vaccine in adults, toddlers, and infants.…”

Section: Table 3: Serum Antibody Responses Prevaccination and 4 Weeksmentioning

confidence: 99%

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial

Groome

Koen

Fix

et al. 2017

The Lancet Infectious Diseases

117

118

View full text Add to dashboard Cite

show abstract

“…Although we could not calculate the VE according to vaccine dose received, because no partial vaccination cases were included in this study, a previous report had indicated that VE for two doses was higher than for one dose only. 23 Third, the type of vaccine, RV1 or RV5, could not be taken into account in the present study because none of the cases had received RV5 vaccine. However, VEs for RV1 and RV5 have been reported to be similar in other studies, 22 but none of these were from Japan.…”

Section: Discussionmentioning

confidence: 96%

Case-Control Study of Rotavirus Vaccine Effectiveness Compared to Test-Negative Controls or Hospital Controls

Araki

Hara

Shimanoe

et al. 2019

Journal of Epidemiology

View full text Add to dashboard Cite

Background Selection of test-negative controls takes less time and costs less than traditional control selection for evaluating vaccine effectiveness (VE). Here, rotavirus VE was evaluated using hospital controls and compared with test-negative controls to determine whether using the latter can substitute for the former. Methods We recorded gastroenteritis in children from 2 months to 2 years of age at six medical facilities in Saga City between January 4th and May 31st, 2014. Stools from all identified acute gastroenteritis patients were tested for rotavirus using immunochromatography. Rotavirus gastroenteritis (RVGE) cases had test-positive stool, whereas test-negative controls had gastroenteritis but no rotavirus infection; hospital controls were outpatients visiting the same facility for indications other than gastroenteritis. Vaccination status was verified by inspecting maternal and child health records, and demographic data were obtained from a questionnaire completed by the patients’ guardians or from the medical records. Unconditional logistic regression analysis was used to adjust for possible confounding factors. Results Sixty-four RVGE cases, 260 test-negative controls, and 589 hospital controls were enrolled. The characteristics of the two control groups, including RV vaccination history, were similar. The RVGE cases were more likely to have used daycare services than children from either of the two control groups. The VE against RVGE estimated using hospital controls was 86.6% (95% confidence interval [CI], 55.9–96.0%), very similar to the VE using test-negative controls (84.9% [95% CI, 49.6–95.5%]). Conclusions The estimated VE using test-negative controls and hospital controls is similar. Therefore, test-negative controls are considered appropriate for establishing VE.

show abstract

Sustained Effectiveness of Rotavirus Vaccine Against Very Severe Rotavirus Disease Through the Second Year of Life, Bolivia 2013–2014

Cited by 28 publications

References 16 publications

The rotavirus vaccine development pipeline

The rotavirus vaccine development pipeline

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial

Case-Control Study of Rotavirus Vaccine Effectiveness Compared to Test-Negative Controls or Hospital Controls

Contact Info

Product

Resources

About